Lingo is Abbott’s over-the-counter continuous glucose monitor (CGM) for nondiabetic people. Withings users will also be able ...

When Dan Heller received his first batch of Dexcom’s latest continuous glucose monitors in early 2023, he decided to run a small experiment: He wore the new biosensor and the previous generation at ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will ...

Dexcom has issued a Class I recall for its G6 glucose sensor Android application due to a defect that causes the app to crash unexpectedly. As a result of the app terminating, users could miss ...

DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ($55.31 – $61.13), levels from which it has bounced significantly in the past ...

Oct 31 (Reuters) - Dexcom (DXCM.O), opens new tab shares tumbled 12.8% on Friday after executives signaled that the medical device maker's 2026 growth forecast could fall short of Wall Street ...

Shares have lagged the market this year, partly due to some public image and regulatory issues. DexCom's stock could drop even more if results falls short of revenue expectations. Whatever happens on ...

A recent investigation by Hunterbrook alleged that Dexcom "dropped the ball" in ensuring the accuracy and reliability of its G7 glucose monitoring device. Some patients reportedly experienced severe ...

People with Type 1 diabetes are estimated to make up to 180 more decisions a day than someone without the disease, according to a study from Stanford University. Each meal, workout, or night’s sleep ...

This diabetes technology offers a continuous stream of data to show a more complete picture of your blood sugars over time. This is different from a fingerstick meter that only represents that moment.

San Diego-based Dexcom Inc., is the target of a class action lawsuit in U.S. district court over the company’s G7 continuous glucose monitors, an action which follows a U.S. FDA warning letter by a ...